Among cell cycle regulators, p16 has attracted particular interest in melanocytic pathology due to its potential role in distinguishing benign nevi—including Spitz nevi, which generally retain strong and diffuse nuclear and cytoplasmic p16 immunohistochemical expression—from melanomas, where loss or marked reduction is frequently observed. The gene discussed is CDKN2A; the disease is melanoma.